𝛼SK or SearchChina Shineway Pharmaceutical (2877.HK) - Strong Growth Momentum Is Expected to Continue in 2023
879 Views11 Apr 2023 08:55
Shineway’s 2022 performance was outstanding. As its TCM formula granules business would seize more market share, Shineway will keep high growth in 2023. It's undervalued considering large cash balance
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- China Shineway Pharmaceutical (2877.HK) 23Q1 - Growth Is Likely to Slow in Coming Quarters11 May 2023
- Valuation System with Chinese Characteristics – the Correct Interpretation and Its Deep Meaning10 May 2023
- China Traditional Chinese Medicine (570.HK) - Looking Forward to a Performance Turnaround in 202312 Apr 2023
- China Shineway Pharmaceutical (2877.HK) - Strong Growth Momentum Is Expected to Continue in 202311 Apr 2023
- China Traditional Chinese Medicine (TCM) Industry - TCM Is Becoming Indispensable in the Portfolio30 Mar 2023
- China Shineway Pharmaceutical (2877.HK) - Some Points Worth the Attention03 Feb 2023
- China Shineway Pharmaceutical (2877HK)-Shineway Is Undervalued, but Downside Risk Is Hard to Control27 Sep 2022
x